Monopar Therapeutics Inc.
MNPR
$80.13
-$2.43-2.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.69% | 37.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.39% | -70.91% | |||
| Operating Income | -0.39% | 70.91% | |||
| Income Before Tax | 6.53% | 75.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.53% | 75.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.53% | 75.97% | |||
| EBIT | -0.39% | 70.91% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 6.68% | 83.14% | |||
| Normalized Basic EPS | 6.69% | 83.14% | |||
| EPS Diluted | 6.68% | 83.14% | |||
| Normalized Diluted EPS | 6.69% | 83.14% | |||
| Average Basic Shares Outstanding | 0.15% | 42.52% | |||
| Average Diluted Shares Outstanding | 0.15% | 42.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||